Drug profile · INN
dimyristoyl lecithin
IMAGENT
dimyristoyl lecithin (IMAGENT) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — dimyristoyl lecithin
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
dimyristoyl lecithin (IMAGENT) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is dimyristoyl lecithin?
dimyristoyl lecithin (IMAGENT) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for dimyristoyl lecithin?
IMAGENT is a marketed brand name for dimyristoyl lecithin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dimyristoyl lecithin?
dimyristoyl lecithin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.